Nucleic acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
CA 2442993 C · Owner: Afar, Daniel E. H. · Inventors: Faris, Mary; Morrison, Robert Kendall; Morrison, Karen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel gene (designated 158P3D2) and its encoded protein and variants , thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue and is aberrantly expressed in the , cancers listed in Table I. Consequently 158P3D2 provides a diagnostic, prognostic prophylactic and/or , therapeutic target for cancer. The 158P3D2 gene or fragment thereof or its , encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T , cells reactive with 158P3D2 can be used in active or passive immunization.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 25, 2002 and granted October 11, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 25, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 25, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.